It’s been a while since we’ve heard about cannabis from Washington D.C. Today, however, there’s been a significant development. A top official at the Department of Health and Human Services (HHS) has announced a recommendation to the Drug Enforcement Administration (DEA) for the reclassification of cannabis.
The HHS’ recommendation was to move cannabis from Schedule I of the Controlled Substances Act to Schedule III. Schedule I is a list of drugs that are dangerous, have no medicinal value, and have a high potential for abuse. While nothing will change immediately, the DEA will now have to conduct a review for themselves to determine whether to follow the HHS recommendation. After that, if the DEA follows the recommendation, 280e – which currently applies to only Schedule I and II substances – will no longer apply to cannabis businesses.
Beyond that, it could lead to institutional banking and lending. Perhaps even more with lenders and capital entering the space.
Not entirely unsurprisingly, cannabis stocks have rallied in the wake of the news. Some stocks have even surged 20-30% in a single day. Notable gains were seen in Ayr Wellness AYRWF, which was up over 29%, Trulieve TCNNF, which saw an increase of over 25%, Curaleaf CURLF, which rose almost 20%, and TerrAscend TRSD, which witnessed record-breaking volume. In addition to these impressive gains.
This looks like it’s potentially a big, big win for the Democrats. We discuss how this situation may unfold and examine some of the implications. Just how political will such a change be? Host Shadd Dales, millennial investor Anthony Varrell, and lead financial writer Benjamin A. Smith have some speculations.
During a recent Twitter Space session held on the handle @thedalesreport, we had a thought-provoking discussion with Jason Wild, TerrAscend Chairman, about whether this recommendation brings us closer to the rescheduling of cannabis. Mr. Wild believes that this is indeed the case. Be sure to catch the discussion, and like and subscribe to keep up with the latest news.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.